DK1227810T3 - Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer - Google Patents

Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer

Info

Publication number
DK1227810T3
DK1227810T3 DK00978553T DK00978553T DK1227810T3 DK 1227810 T3 DK1227810 T3 DK 1227810T3 DK 00978553 T DK00978553 T DK 00978553T DK 00978553 T DK00978553 T DK 00978553T DK 1227810 T3 DK1227810 T3 DK 1227810T3
Authority
DK
Denmark
Prior art keywords
fatty acid
inhibition
cpt
malonyl coa
fas
Prior art date
Application number
DK00978553T
Other languages
English (en)
Inventor
Craig A Townsend
Francis P Kuhajda
Ellen S Pizer
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of DK1227810T3 publication Critical patent/DK1227810T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Epoxy Compounds (AREA)
DK00978553T 1999-11-12 2000-11-13 Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer DK1227810T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16476899P 1999-11-12 1999-11-12
US16476599P 1999-11-12 1999-11-12

Publications (1)

Publication Number Publication Date
DK1227810T3 true DK1227810T3 (da) 2006-10-23

Family

ID=26860829

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00978553T DK1227810T3 (da) 1999-11-12 2000-11-13 Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer

Country Status (12)

Country Link
US (1) US20020187534A1 (da)
EP (1) EP1227810B8 (da)
JP (1) JP2003513920A (da)
KR (4) KR20090130151A (da)
AT (1) ATE330598T1 (da)
AU (3) AU784495B2 (da)
CA (1) CA2391277A1 (da)
DE (1) DE60028996T2 (da)
DK (1) DK1227810T3 (da)
ES (1) ES2267587T3 (da)
PT (1) PT1227810E (da)
WO (1) WO2001034145A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354196B1 (en) * 2000-11-27 2010-09-15 Minerva Biotechnologies Corporation Diagnostics, drug screening and treatment for cancer
WO2003037323A2 (en) * 2001-10-26 2003-05-08 MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction
EA007029B1 (ru) * 2002-02-08 2006-06-30 Джон Хопкинс Юниверсити Скул Оф Медсин Стимуляция срт-1 как средство уменьшения веса
CN101633650A (zh) * 2002-07-01 2010-01-27 法斯根有限责任公司 新化合物、包含该化合物的药物组合物及该化合物的应用方法
KR20050111573A (ko) * 2002-10-31 2005-11-25 파스젠, 엘엘씨. 지방산 신타제 억제제에 의한 암 발생 억제 방법
WO2004071458A2 (en) 2003-02-13 2004-08-26 Albert Einstein College Of Medicine Of Yeshiva University REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
EP1651207A4 (en) * 2003-06-12 2008-10-01 Univ Colorado SYSTEMS AND METHOD FOR THE TREATMENT OF INFLAMMATORY AND PROLIFERATIVE DISEASES AND WOUNDS OF HUMANS WITH FATTY ACID SUBSTANCE CHEMICALS AND / OR GLYCOLYTIC INHIBITORS
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
ITMI20040230A1 (it) * 2004-02-12 2004-05-12 Defiante Farmaceutica Lda Composti ad attivita' antitumorale
WO2006116217A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of Colorado Therapeutic bifunctional compounds
AU2006242667A1 (en) 2005-05-02 2006-11-09 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition
WO2007117038A1 (ja) * 2006-04-07 2007-10-18 Japanese Foundation For Cancer Research 癌の予防・治療剤
US20100292302A1 (en) * 2007-03-08 2010-11-18 Mak Tak W Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity
CA2680366C (en) 2007-03-09 2016-06-21 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
US20090053804A1 (en) * 2007-07-27 2009-02-26 Vesta Therapeutics, Inc. Methods of reducing intracellular fats from mammalian cells
US8680282B2 (en) * 2007-08-01 2014-03-25 University Health Network Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
WO2009105230A2 (en) 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
CA2730773A1 (en) 2008-07-14 2010-01-21 Martha Karen Newell Methods and products for treating proliferative diseases
JP5317919B2 (ja) * 2009-10-05 2013-10-16 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
CN107660213B (zh) 2015-02-10 2023-01-13 米纳瓦生物技术公司 人源化抗MUCl＊抗体
SG11201903254PA (en) * 2016-10-17 2019-05-30 Univ Keio Undifferentiated stem cell-removing agent, and method for removing undifferentiated stem cells
WO2020212362A1 (en) * 2019-04-15 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) A method of profiling the energetic metabolism of a population of cells
CN113549702A (zh) * 2021-09-14 2021-10-26 北京大学第三医院（北京大学第三临床医学院） 一种人脂肪酸代谢关键酶基因检测方法以及试剂盒
CN113604573A (zh) * 2021-09-14 2021-11-05 北京大学第三医院（北京大学第三临床医学院） 一种使用至少八种脂肪酸代谢关键酶基因检测方法以及试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
PT651636E (pt) * 1992-07-24 2003-02-28 Univ Johns Hopkins Quimioterapia contra o cancro
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Also Published As

Publication number Publication date
EP1227810B8 (en) 2006-08-16
KR20020060736A (ko) 2002-07-18
EP1227810B1 (en) 2006-06-21
ATE330598T1 (de) 2006-07-15
DE60028996D1 (de) 2006-08-03
DE60028996T2 (de) 2007-02-08
JP2003513920A (ja) 2003-04-15
AU2009227836A1 (en) 2009-11-05
KR20090031957A (ko) 2009-03-30
AU784495B2 (en) 2006-04-13
ES2267587T3 (es) 2007-03-16
KR20090130151A (ko) 2009-12-17
US20020187534A1 (en) 2002-12-12
EP1227810A1 (en) 2002-08-07
PT1227810E (pt) 2006-11-30
CA2391277A1 (en) 2001-05-17
AU2006203005A1 (en) 2006-08-10
WO2001034145A1 (en) 2001-05-17
AU1600701A (en) 2001-06-06
KR20070106648A (ko) 2007-11-02

Similar Documents

Publication Publication Date Title
DK1227810T3 (da) Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer
Tseng et al. Inhibition of MDA‐MB‐231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation‐mediated p21WAF1/CIP1 expression
Anastasiou Tumour microenvironment factors shaping the cancer metabolism landscape
Mullen et al. Progress in the development of fatty acid synthase inhibitors as anticancer targets
Yang et al. What has passed is prolog: new cellular and physiological roles of G6PD
Crack et al. Potential contribution of NF-κB in neuronal cell death in the glutathione peroxidase-1 knockout mouse in response to ischemia-reperfusion injury
Gogebakan et al. Role of propolis on tyrosine hydroxylase activity and blood pressure in nitric oxide synthase-inhibited hypertensive rats
MA27609A1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
ATE455550T1 (de) Verwendung eines extraktes aus angelica sinensis als wachstumsinhibitor von krebszellen in der tumortherapie
Li et al. LFG-500 inhibits the invasion of cancer cells via down-regulation of PI3K/AKT/NF-κB signaling pathway
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
ATE487475T1 (de) Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer
Velmurugan et al. Excavatolide B inhibits nonsmall cell lung cancer proliferation by altering peroxisome proliferator activated receptor gamma expression and PTEN/AKT/NF‐Kβ expression
Coronel-Hernández et al. Aberrant metabolism as inductor of epigenetic changes in breast cancer: therapeutic opportunities
NO20020829L (no) Ny anvendelse av docetaxel for behandling av hepatoma
Wang et al. Apigenin inhibits human SW620 cell growth by targeting polyamine catabolism
EP2633856A3 (en) ATP citrate lyase inhibitors for treating cancer
EA200500958A1 (ru) Дейтерированные производные катехоламина, а также лекарственные средства, содержащие эти соединения
EA200601471A1 (ru) Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты)
Shatanawi et al. Arginase inhibition suppresses breast cancer cell proliferation
Flores-López et al. Parthenolide and DMAPT induce cell death in chronic myeloid leukemia cells via generation of reactive oxygen species
Dando et al. New Insights into Metabolic Alterations and Mitochondria Re-Arrangements in Pancreatic Adenocarcinoma
최종근 et al. Comparative Modeling of Human Tyrosinase-an Important Target for Developing Skin Whitening Agents
Samara et al. Deferasirox Induces Apoptosis in Mantle Cell Lymphoma in a Mechanism Involving Cyclin-D1, p53 and the Ribonucleotide Reductase
범진필 Stalility of Paclitaxel with Cephalosporines in 0.8 Sodium Chloride Injection and 5 Dextrose Injection During Simulated Y-Site Administration